Tuesday, March 04, 2025 | 08:08 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Natco Pharma extends rally on ties up with Gilead on hepatitis C drugs

The stock has moved higher by 8% to Rs 1,542, extending its previous day's 4% gain on NSE,

SI Reporter Mumbai
Natco Pharma has moved higher by 8% to Rs 1,542, extending its previous day’s 4% gain on NSE, after the company announced that it has signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines.

The medicines include sofosbuvir, ledipasvir/sofosbuvir and the investigational NS5A inhibitor GS-5816 that was being evaluated in phase 3 clinical studies as part of a single tablet regimen combining the compound and sofosbuvir for treating all six genotypes of hepatitis C, Natco Pharma said in a press release.

The company said, the agreement allows Natco to expand access to these chronic hepatitis C medicines in 91 developing countries.

The stock opened at Rs 1,444 and touched high of Rs 1,543 on NSE. The trading volumes on the counter more than doubled with a combined 144,275 shares changed hands against an average sub 50,000 shares that were traded daily in past two weeks on NSE and BSE.
 
 

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 03 2015 | 10:27 AM IST

Explore News